Articles tagged "Viral therapy"

2021 American Transplant Congress
Clinical Outcomes of Solid Organ Transplant Recipients Treated with Remdesivir and Convalescent Plasma for Covid-19 at the Largest Transplant Center in the United States
A. Fernandez, S. Anjan, A. Chandorkar, D. de Lima, R. Zamora, L. A. Mendez-Castaner, J. Simkins, J. Camargo, M. Morris, M. Loebe, J. Bauerlein, C. O’Brien, N. Sinha, G. Burke, G. Ciancio, A. Mattiazzi, R. Vianna, L. Abbo, G. Guerra, Y. Natori
Miami Transplant Institute, Jackson Health System, Miami, FL
*Purpose: Solid organ transplant recipients (SOTr) are at high risk for severe disease with SARS-CoV-2. Data on efficacy of potential treatment options and long-term outcomes…
2021 American Transplant Congress
Longitudinal Antibody Response and Viral Loads in Covid-infected Organ Transplant Recipients
T. M. Marinelli, V. H. Ferreira, M. Ierullo, V. Kulasingham, B. Majchrzak-Kita, C. Rotstein, S. Husain, S. Hosseini, A. Humar, D. Kumar
UHN, Toronto, ON, Canada
*Purpose: The full spectrum of COVID-19 disease and the impact of disease severity on antibody response and viral shedding dynamics in transplant patients is unclear.…
2021 American Transplant Congress
Leflunomide Therapy for Treatment of Bk Viremia in Pediatric Kidney Transplant Recipients
A. Aldieri¹, M. Chandran², D. Matossian³, B. Magella⁴, D. Lazear⁴, M. Bock², E. Blanchette²
¹Children's Hospital Colorado, Denver, CO, ²Children's Hospital Colorado, Aurora, CO, ³Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH
*Purpose: BK viremia (BKV) after kidney transplantation (KT) poses significant risk for BK virus-associated nephropathy (BKVN) and impacts graft survival. Conventional treatment involves reduction of…
2021 American Transplant Congress
Influence of Induction Therapy and Antiretroviral Regimen on Outcomes in HIV Positive Renal Transplant Recipients
C. Rogers Marks¹, C. Durand², J. Hand³, M. Abidi⁴, M. Malinis⁵, B. Barnaba², H. Patel⁶, C. D. Alonso⁶
¹Massachussetts General Hospital, Boston, MA, ²Johns Hopkins Medical Center, Baltimore, MD, ³Ochsner Medical Center, New Orleans, LA, ⁴Univ. of Colorado, Aurora, CO, ⁵Yale, New Haven, CT, ⁶Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: Transplantation of HIV+ individuals has become more common over the past decade with increasing data supporting good outcomes. Questions remain regarding the impact of…
2021 American Transplant Congress
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
Z. A. Yetmar¹, E. Beam¹, J. C. O'Horo¹, R. Ganesh², D. M. Bierle², L. Brumble³, M. T. Seville⁴, R. R. Razonable¹
¹Infectious Diseases, Mayo Clinic, Rochester, MN, ²General Internal Medicine, Mayo Clinic, Rochester, MN, ³Infectious Diseases, Mayo Clinic, Jacksonville, FL, ⁴Infectious Diseases, Mayo Clinic, Scottsdale, AZ
*Purpose: Bamlanivimab and casirivimab-imdevimab are authorized for emergency use treatment of mild-to-moderate COVID-19 in patients at high-risk for progression to severe disease or hospitalization. For…
2021 American Transplant Congress
Outcomes of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
G. Gupta, I. Yakubu, P. Kimball, L. Kang, K. Mitchell, M. Shinbashi, D. Kumar, I. Moinuddin, L. Kamal, A. King, C. Bhati, M. Levy, A. Cotterell, A. Sharma, R. Sterling
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…
2021 American Transplant Congress
Transplanting Hepatitis C Infected Organs Into Uninfected Recipients: A Pharmacy Perspective
M. L. Holt, A. James, K. Gutierrez, T. Sparkman, J. Banbury, D. Jones
University of Alabama at Birmingham Hospital, Birmingham, AL
*Purpose: Due to direct acting antivirals (DAAs), hepatitis C virus (HCV) positive patients are now resources for organ transplantation in HCV negative recipients. Our institution…
2021 American Transplant Congress
The Use of Hcv Nat+ Organs in Hcv Negative Recipients with On-site Specialty Pharmacy Services: A Win for the Patient, the Transplant Center, and Society?
M. Person, N. Patel, W. Simerlein, H. Meadows, D. DuBay, D. Taber
Medical University of South Carolina, Charleston, SC
*Purpose: Use of HCV AB positive organs (HCV AB+) with active viremia (NAT+) relies on appropriate and timely use of direct acting antiviral therapies (DAA).…
2021 American Transplant Congress
Influence of Immunosuppressant Management on Mortality in Kidney Transplant Recipients Hospitalized with COVID-19
Y. Fenig, A. Santeusanio, M. Menon, C. Liu, M. Rana, R. Shapiro
Mount Sinai Hospital, New York, NY
*Purpose: Kidney transplant recipients are thought to be at high risk for mortality from COVID-19 due to the necessity for chronic immunosuppressive therapy to prevent…
2021 American Transplant Congress
Current Practices for Management and Treatment of COVID-19 in Immunocompromised Adults: A Survey of Institutions
H. H. Nam¹, S. Aslam², O. Beaird³, G. Forrest⁴, M. Fung⁵, A. Limaye⁶, A. Multani³, J. Nelson⁷, R. Rakita⁶, L. Strasfeld⁸, J. Schaenman³
¹Medicine, University of California - Irvine, Orange, CA, ²Division of Infectious Diseases and Global Public Health, University of California - San Diego, San Diego, CA, ³Medicine, University of California - Los Angeles, Los Angeles, CA, ⁴Medicine, Rush University, Chicago, IL, ⁵Medicine, University of California - San Francisco, San Francisco, CA, ⁶Medicine, University of Washington, Seattle, WA, ⁷Medicine, Stanford University, Palo Alto, CA, ⁸Medicine, Oregon Health and Science University, Portland, OR
*Purpose: The optimal testing strategy for solid organ transplantation (SOT) donor and recipient evaluation, as well as treatment for COVID-19 is unknown. We assessed the…